International registry for patients with hemophilia and bleeding disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The World Bleeding Disorders Registry (WBDR) is an international observational registry aimed at collecting standardized data from patients diagnosed with hemophilia A, hemophilia B, and von Willebrand Disease. It seeks to enroll over 10,000 patients from at least 200 hemophilia treatment centers across more than 50 countries. The registry will gather information on disease type, severity, symptoms, and treatment, with the goal of improving clinical practice and addressing scientific questions through real-world data. Participation requires informed consent and commitment from treatment centers to long-term patient follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients of participating Hemophilia Treatment Centres with Hemophilia A or B, or von Willebrand Disease

Exclusion Criteria:

* none

Where it's running

• World Federation of Hemophilia
  Montreal, Quebec, Canada Recruiting

Study contacts

• Study coordinator: Donna Coffin, M.Sc.
• Email: dcoffin@wfh.org
• Phone: +15148757944

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ATHNdataset registry for people with bleeding and clotting disorders

  This registry collects health, treatment, and patient-reported information from people with bleeding and clotting disorders seen at ATHN-affiliated centers to help improve care and outcomes.

  Recruiting American Thrombosis and Hemostasis Network · Hickory, North Carolina · NCT06820515

• SR604: a new treatment tested in adults with Hemophilia A/B or congenital Factor VII deficiency

  This study tests a single and multiple doses of SR604 to see if it is safe and effective for adults with Hemophilia A or B, with or without inhibitors, and for those with congenital Factor VII deficiency.

  Recruiting at 7 sites Phase 1/2 Shanghai RAAS Blood Products Co., Ltd. · Changsha and 8 other locations · NCT07644832

• Is synovial proliferation in haemophilia joints active or inactive?

  This project will test whether ultrasound, MRI and elastography can tell if subclinical synovial proliferation in people with severe haemophilia is currently active so clinicians can treat earlier.

  Recruiting UMC Utrecht · Utrecht · NCT06809972

• Observational study of blood clotting and bleeding disorders in Chinese patients

  This study looks at blood clotting and bleeding problems in Chinese patients to see how common they are and what factors might affect them.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality and 4 other locations · NCT06727669

• Evaluating the safety and effects of SR604 in healthy individuals and those with Hemophilia A or B

  This study is testing a new drug called SR604 to see if it's safe and effective for healthy people and those with Hemophilia A or B.

  Recruiting at 8 sites Phase 1 Equilibra Bioscience LLC · Glendale, California and 9 other locations · NCT06349473

• Non-invasive prenatal diagnosis for single gene disorders

  This study is testing a new way to safely diagnose single-gene disorders in unborn babies using a simple blood test from the mother, starting as early as 9 weeks into the pregnancy.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT06147414

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.